Self administration
ProcedureSubjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
NCT Number: NCT00770887
The purpose of this study is to assess continuation rates and patient satisfaction with self administration subcutaneous depot medroxyprogesterone acetate.
Looking for future studies?
Notify Me18 year–50 year
Female
Observational
Planned Parenthood of Southwest and Central Florida, Fort Myers, Florida, United States
This observational study will include new or current Depo Provera users who express interest in attempting subcutaneous self administration of depot medroxyprogesterone acetate. Candidates will be taught self administration by a clinic assistant at Planned Parenthood of Southwest and Central Florida. Patients who are able to correctly self administer the medication and wish to attempt to continue home self administration, will be provided the supplies and educational materials to do so. Continuation rates and satisfaction with this method will be assessed using preaddressed surveys that patients will return with the above information.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Has contraindications to DMPA use:
Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
Time frame: At onset of trial and every 12 weeks for 1 year
Time frame: Every 12 weeks for 1 year
Looking for future studies?
Notify MeUniversity of North Carolina, Chapel Hill
Other
Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate: A Pilot Observational Study of Feasibility and Acceptability
Acronym: SAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04355312
Adnexal Diseases, Cysts
Clermont-Ferrand, France
View Trial DetailsNCT04487639
COVID-19, Coronaviridae Infections
Reims, France
View Trial DetailsNCT07740187
Female Infertility, Female Urogenital Diseases
Las Vegas, Nevada, United States
View Trial DetailsNCT06134479
Fertility
Barcelona, Spain
View Trial Details